Skip to main content
Can-Fite BioPharma Ltd. logo

Can-Fite BioPharma Ltd. — Investor Relations & Filings

Ticker · CANF ISIN · IL0010944739 LEI · 549300ZLRH6GSBOHFZ59 TA Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2026-01-17 Board/Management Inform…
Country IL Israel
Listing TA CANF

About Can-Fite BioPharma Ltd.

https://www.canfite.com/

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Board/Management Information Classification · 1% confidence The document is a Form 6-K filed with the SEC by Can-Fite Biopharma Ltd. The content explicitly announces the resignation of a member of the Board of Directors, Yaacov Goldman, effective immediately. According to the filing definitions, announcements regarding changes in the board of directors are classified as 'MANG' (Board/Management Information).
2026-01-17 English
Other Report or Announcement
Board/Management Information Classification · 1% confidence The document is a regulatory filing from Can-Fite Biopharma Ltd. submitted to the Israel Securities Authority. It explicitly states that a director has resigned from the Board and all committees, effective immediately. This is a notification of a change in the company's board of directors, which falls under the 'Board/Management Information' category.
2026-01-17 English
6-K Filing
Foreign Filer Report
2026-01-16 English
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Can-Fite BioPharma Ltd. A Form 6-K is a report used by foreign private issuers to disclose material information that is not otherwise covered by a specific periodic report. In this instance, the document serves to announce the granting of a Brazilian patent for a drug candidate. Since this is a general regulatory announcement of a corporate development (patent grant) filed via a standard SEC form, it falls under the 'Regulatory Filings' category.
2025-12-29 English
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Can-Fite Biopharma Ltd submitted to the Israel Securities Authority. It explicitly states 'The corporation scheduled the publication of the report to 29/12/2025' and 'Attached hereto is a report on Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction'. Following the 'Menu vs Meal' rule, since this is a short notification announcing the publication of an attached report, it is classified as a Report Publication Announcement (RPA).
2025-12-29 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2025-12-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.